BankopediaBankopedia

3 August 2026

Bankopedia Banking Digest — 2026-08-03 #127

15 articles
  1. #1
    economic_timesneutral

    RBI MPC Holds Course Amid Global Headwinds

    The Reserve Bank of India's Monetary Policy Committee meeting opens with economists widely expecting a rate hold amid elevated global crude prices and a hawkish U.S. Federal Reserve. Domestic inflation, liquidity conditions, and growth remain the primary drivers of RBI's policy calculus rather than global monetary trends.

    RBI expected to hold rates, prioritising domestic inflation and liquidity over global cues.

    monetary_policy
  2. #2
    economic_timesneutral

    Banks Seek Smarter UPI Fraud Safeguards

    Indian banks are proposing a 'Yes-No' confirmation prompt for high-value Unified Payments Interface peer-to-peer transfers as an alternative to the RBI's proposed one-hour delayed credit mechanism to curb digital fraud. Banks also suggest raising the transaction threshold triggering safeguards from ₹10,000 to ₹20,000–₹25,000 to avoid dampening digital payment adoption.

    Banks propose real-time consent prompt for UPI transfers to counter fraud without slowing payments.

    paymentsdigital_bankingregulation
  3. #3
    economic_timespositive

    PNB Prioritises Subsidiary Value Over Monetisation

    Punjab National Bank Managing Director Ashok Chandra rules out any subsidiary monetisation in the current financial year, preferring instead to build value within its insurance, housing finance, and other units. The bank's capital adequacy ratio of 18.13% — well above the 11.5% regulatory minimum — means no fresh market fundraising is needed to fund growth.

    PNB's 18.13% capital adequacy ratio removes any near-term need for subsidiary sales or market fundraising.

    banking_supervisioncorporate_finance
  4. #4
    economic_timespositive

    SEZ Forex Rule Reform Targets Domestic Service Trade

    The government is planning to amend the Special Economic Zone Act, 2005 to allow service exports from SEZs to Domestic Tariff Areas to be settled in Indian rupees rather than mandatory foreign exchange, aligning the rule with Goods and Services Tax law. Industry argues the current foreign-exchange realisation requirement inflates transaction costs and disadvantages Indian SEZ units against foreign competitors.

    Proposed SEZ amendment will allow rupee settlement for domestic service transactions, cutting forex conversion costs.

    regulationforex
  5. #5
    economic_timespositive

    Bank of Maharashtra Cuts Home Loan Rate to 7%

    Bank of Maharashtra has launched a limited-period 'Monsoon Dhamaka' scheme offering home loans starting at 7% per annum with zero processing and documentation fees. The bank also offers car loans at 7.45%, positioning both products among the lowest rates in the Indian lending market.

    Bank of Maharashtra's 7% home loan rate with zero fees ranks among India's lowest current offerings.

    credit_marketscorporate_finance
  6. #6
    economic_timesneutral

    India's Selective Gate on Border-Country FDI

    India approved just one Chinese foreign direct investment proposal worth ₹1 crore in FY26 under the Press Note 3 land-border screening regime, while clearing 13 investments from Hong Kong. Overall, the government sanctioned 63 FDI proposals worth ₹10,292.67 crore in FY26, with Singapore leading in value at ₹3,259.88 crore.

    India approved only one Chinese FDI proposal, worth ₹1 crore, in the entire FY26.

    regulationcapital_markets
  7. #7
    reserve_bank_of_indianeutral

    RBI Money Markets Signal Surplus Liquidity

    The Reserve Bank of India's money market operations on July 31, 2026 recorded overnight segment volumes of ₹16,132.08 crore at a weighted average rate of 5.28%. Banks parked ₹2,44,708 crore under the Standing Deposit Facility at 5.00%, signalling continued surplus liquidity in the system.

    Banks deposited ₹2,44,708 crore at RBI's Standing Deposit Facility, reflecting ample system liquidity.

    monetary_policypayments
  8. #8
    financial_expressnegative

    IBC Resolution Crisis Demands Structural Reform

    Insolvency and Bankruptcy Code (IBC) resolutions fell to a 13-quarter low of just 36 in Q4 FY26, with annual resolutions dropping to 665 in FY26 — nearly half the level of three years ago — as creditors lose confidence in the process. The government is responding with legislative reforms including a new out-of-court resolution framework for designated financial institutions.

    IBC resolutions hit a 13-quarter low of 36 in Q4 FY26, prompting urgent legislative overhaul.

    npa_resolutionregulation
  9. #9
    moneycontrolneutral

    Manipal Health IPO Allotment Amid Weak GMP

    Manipal Health Enterprises' ₹9,275 crore IPO was subscribed 4.92 times by July 31, with the Qualified Institutional Buyers portion covered 8.25 times, ahead of its scheduled listing on August 5. However, a grey market premium of negative ₹7 signals a weak debut is anticipated.

    Manipal Health's ₹9,275 Cr IPO subscribed 4.92x but grey market signals a below-issue-price listing.

    capital_markets
  10. #10
    financial_expressneutral

    Japan-US Yen Intervention Rattles Dollar Markets

    Japan's finance ministry confirmed a rare coordinated yen-buying intervention with the United States to arrest the currency's slide to 40-year lows, sending the yen to a three-month high of around 155.20 per dollar. Both governments warned they will not hesitate to intervene again if the yen resumes its decline.

    Japan and the US jointly intervened to lift the yen from 40-year lows, warning of further action.

    forexmonetary_policy
  11. #11
    financial_expresspositive

    Bajaj Finance and Auto Signal Multi-Timeframe Breakout

    Technical charts for Bajaj Finance and Bajaj Auto show multi-timeframe alignment, signalling a potential new leg of long-term wealth creation. The Relative Strength Index (RSI) holding above 60 across quarterly, monthly, and weekly charts indicates sustained buying interest despite short-term pullbacks.

    RSI above 60 across all timeframes signals renewed bullish momentum in both Bajaj stocks.

    capital_markets
  12. #12
    hindu_businesslinepositive

    L&T Finance Charts Retail Delivery Roadmap to 2031

    L&T Finance targets a 2.3x expansion of its loan book to ₹3 lakh crore by 2031, anchoring its Lakshya 2026–31 strategy on retail delivery after completing a wholesale-to-retail transformation. MD and CEO Sudipta Roy says the non-banking financial company (NBFC) is also open to exploring a digital banking licence.

    L&T Finance targets ₹3 lakh crore loan book by 2031, implying ~20% CAGR from current ₹1.3 lakh crore.

    financial_inclusiondigital_banking
  13. #13
    moneycontrolneutral

    Dixon Technologies Balances Revenue Surge Against Margin Pressure

    Dixon Technologies posted a 21.1% year-on-year revenue jump to ₹15,548 crore in Q1 FY27, but EBITDA margins contracted to 3% from 3.8%, sending shares down over 2%. Nomura retained its Buy rating and raised its target price to ₹17,086, citing improved growth visibility from new approvals and the Mobile Phone Manufacturing Scheme.

    Dixon Q1 FY27 net profit nearly tripled year-on-year despite EBITDA margin compression to 3%.

    capital_markets
  14. #14
    financial_expressnegative

    Capital One Cites AML Rules in Trump Account Closures

    Capital One has publicly linked its closure of over 300 Trump Organisation bank accounts to anti-money laundering (AML) compliance concerns in a federal court filing. The Trump Organisation denies wrongdoing and alleges the bank illegally cut off services for political reasons.

    Capital One cites AML concerns — not political bias — for closing 300+ Trump Organisation bank accounts.

    banking_supervisionregulation
  15. #15
    moneycontrolpositive

    Dr Reddy's FDA Approval Unlocks Biosimilar Growth Pipeline

    Dr Reddy's Laboratories received US FDA approval for biosimilar Rituximab, lifting shares 1.5% and signalling compliance of its Bachupally biologics facility. Nomura retains its Buy rating, projecting the upcoming biosimilar Abatacept launch could deliver $431 million in revenue by FY29 and 30% earnings upside.

    FDA Rituximab approval clears the path for Dr Reddy's higher-value biosimilar Abatacept US launch.

    capital_markets